演題詳細

一般口演 / Oral Session

一般口演 8 (Oral Session 8) :MDS:臨床 2

print

日程
2013年10月11日(金)
時間
10:30 - 11:30
会場
第6会場 / Room No.6 (ロイトン札幌 2F エンプレス)
座長・司会
前田 嘉信 (Yoshinobu Maeda):1
1:岡山大学病院 血液・腫瘍・呼吸器・アレルギー内科
 
前へ戻る

Efficacy and safety of azacitidine in patients with MDS/AML in clinical practice

演題番号 : OS-1-40

根本 朋恵 (Tomoe Nemoto):1、渡部 玲子 (Reiko Watanabe):1、佐川 森彦 (Morihiko Sagawa):1、富川 武樹 (Tatsuki Tomikawa):1、多林 孝之 (Takayuki Tabayashi):1、高橋 康之 (Yasuyuki Takahashi):1、木村 勇太 (Yuta Kimura):1、得平 道英 (Michihide Tokuhira):1、森 茂久 (Shigehisa Mori):1、木崎 昌弘 (Masahiro Kizaki):1

1:Department of Hematology, Saitama Medical Center, Saitama Medical University, Japan

 

Recent clinical studies reported that azacitidine (AZA) could improve survival of patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Here, we report our experience with AZA treatment for MDS in a single institution. Nineteen patients with MDS and AML (median age, 69 years; range, 40-75 years) who received AZA from May 2011 to January 2013 at our institution were analyzed retrospectively. Diagnoses included RCMD (n=6), RAEB-1 (n=5), RAEB-2 (n=2) and AML (n=6). Subcutaneous injection of 75 mg/m2 AZA for 5 consecutive days in a 28-day cycle was planned. However, three patients could not receive the second cycle of AZA because of adverse effects, including pneumonia (n=2) and sepsis (n=1). They revealed severe neutropenia at the start of AZA treatment. The median number of treatment courses was 5 (1-19 courses). During the median observation period of 9 months (2-19 months), eight patients died because of disease progression (n=7) and sepsis (n=1). According to IWG 2006 criteria, hematologic responses were obtained as erythroid responses in 6 patients, platelet responses in 7 patients and neutrophil responses in 5 patients. Among the 15 evaluable patients, 4 patients obtained partial remission (PR) and 6 patients had stable disease (SD). Hematological adverse events of grade 3/4 were experienced in 17 of 19 (89%) patients. AZA showed considerable efficacy in patients with MDS and AML and will likely improve the outcomes for such patients. However, we need to pay careful attention to infectious adverse events in severely neutropenic patients.

前へ戻る